Ocugen Inc
Company Profile
Business description
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Contact
11 Great Valley Parkway
MalvernPA19355
USAT: +1 484 328-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
95
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,773.60 | 6.30 | -0.07% |
| CAC 40 | 7,569.61 | 11.45 | 0.15% |
| DAX 40 | 23,684.64 | 186.31 | 0.79% |
| Dow JONES (US) | 42,982.43 | 106.59 | -0.25% |
| FTSE 100 | 8,729.16 | 10.41 | 0.12% |
| HKSE | 24,325.40 | 149.27 | -0.61% |
| NASDAQ | 19,973.55 | 61.02 | 0.31% |
| Nikkei 225 | 39,584.58 | 642.51 | 1.65% |
| NZX 50 Index | 12,480.05 | 19.09 | 0.15% |
| S&P 500 | 6,092.16 | 0.02 | -0.00% |
| S&P/ASX 200 | 8,550.80 | 8.40 | -0.10% |
| SSE Composite Index | 3,448.45 | 7.52 | -0.22% |